Complaints have been circulating regarding the decision made by the Health Insurance Review and Assessment Service (HIRA) to reduce reimbursement on medical care reimbursement claims for medicines containing 'choline alfoscerate,' a brain function-improving agent.

Medicines-containing choline alfoscerate received selective reimbursement decision during the re-evaluation of reimbursement appropriateness. However, its previous reimbursement criterion is being maintained due to pharmaceutical companies fling lawsuits.

However, HIRA requires even stricter criterion by designating medicines-containinig choline alfoscerate as targets for 'intensive screening.'

According